Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer

• DOI: 10.1200/jco.2002.20.4.937
• Publication Date: 2017-02-24T08:46:55Z
• Authors: David J. Vaughn; Catherine M. Broome; Maha Hussain; John C. Gutheil; Avi B. Markowitz
• Keywords: Urothelial cancer; Regimen; Refractory (planetary science); Chemotherapy regimen

PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. PATIENTS AND METHODS: Patients cancer who had received one prior systemic chemotherapy regimen for disease evidence progression were eligible enrollment. 80 mg/m 2 by 1-hour intravenous infusion weekly. A cycle therapy consisted four treatments. RESULTS: The study enrolled 31 patients. Mean age was 66 years, 45% three or more involved metastatic sites. Only 26% responded to chemotherapy. median number cycles delivered (range, eight) at a mean dose 79 . Three achieved partial response (10%; 95% confidence interval, 0% 20%). Median time 2.2 months, overall survival 7.2 months. Therapy well tolerated minimal hematologic toxicity. Grade 3 nonhematologic toxicities also uncommon. CONCLUSION: Although rate modest, chemotherapy-refractory nature population should be considered.